[New targets and drugs for treatment of lipid metabolism disorders]

Pharm Unserer Zeit. 2007;36(2):142-8. doi: 10.1002/pauz.200600213.

[Article in German]

Authors

Oliver Rau¹, Heiko Zettl, Laura Popescu, Dieter Steinhilber, Manfred Schubert-Zsilavecz

Affiliation

¹ Institut für Pharmazeutische Chemie der Johann Wolfgang Goethe-Universität, Frankfurt.

PMID: 17425000
DOI: 10.1002/pauz.200600213

No abstract available

Publication types

Review

MeSH terms

Animals
Anticholesteremic Agents / pharmacology
Anticholesteremic Agents / therapeutic use
Antioxidants / therapeutic use
Carrier Proteins / antagonists & inhibitors
Cholesterol Ester Transfer Proteins / drug effects
Enzyme Inhibitors / pharmacology
Enzyme Inhibitors / therapeutic use
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
Hypolipidemic Agents / pharmacology*
Hypolipidemic Agents / therapeutic use*
Intestinal Absorption / drug effects
Lipid Metabolism Disorders / drug therapy*
Peroxisome Proliferator-Activated Receptors / agonists
Sterol O-Acyltransferase / antagonists & inhibitors

Substances

Anticholesteremic Agents
Antioxidants
Carrier Proteins
Cholesterol Ester Transfer Proteins
Enzyme Inhibitors
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypolipidemic Agents
Peroxisome Proliferator-Activated Receptors
microsomal triglyceride transfer protein
Sterol O-Acyltransferase